Get the Stockscreener App
8.33
4.69%
-0.41
Stoke Therapeutics Inc stock is traded at $8.33, with a volume of 1.04M.
It is down -4.69% in the last 24 hours and down -15.00% over the past month.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
See More
Previous Close:
$8.74
Open:
$8.9
24h Volume:
1.04M
Relative Volume:
1.44
Market Cap:
$441.21M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-3.5148
EPS:
-2.37
Net Cash Flow:
$-82.68M
1W Performance:
-22.00%
1M Performance:
-15.00%
6M Performance:
-43.72%
1Y Performance:
+55.41%
1-Day Range:
$8.20
$9.14
1-Week Range:
$8.20
$11.11
52-Week Range:
$5.21
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
8.33 | 441.21M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Equities Analysts Offer Predictions for STOK Q1 Earnings - Defense World
HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings - Defense World
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
Trading (STOK) With Integrated Risk Controls - Stock Traders Daily
Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital - Defense World
Stoke Therapeutics’ Collaboration with BioGen - Global Legal Chronicle
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN
Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP
Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum
Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – Here’s Why - Defense World
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright - Defense World
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - BioSpace
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights
Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright - Smartphone Magazine
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance
Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals
Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg
BTIG maintains Stoke Therapeutics stock with $29 target By Investing.com - Investing.com UK
HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating - Marketscreener.com
Biogen And Stoke Therapeutics Enter Into Collaboration -February 18, 2025 at 10:00 am EST - Marketscreener.com
Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating - TipRanks
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen -February 18, 2025 at 09:39 am EST - Marketscreener.com
Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT
Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
Biogen, Stoke partner for Dravet syndrome treatment - Investing.com
Biogen, Stoke partner for Dravet syndrome treatment By Investing.com - Investing.com South Africa
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch
Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT
Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha
Sector Update: Health Care Stocks Softer Wednesday Afternoon -February 12, 2025 at 01:47 pm EST - Marketscreener.com
SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Sector Update: Health Care Stocks Retreat Late Afternoon -February 12, 2025 at 03:54 pm EST - Marketscreener.com
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat
Long Term Trading Analysis for (STOK) - Stock Traders Daily
Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater
STOK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2%Here's Why - MarketBeat
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? - MSN
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts - Armenian Reporter
Stoke Therapeutics Inc (STOK) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Stoke Therapeutics Inc: Rising -28.33% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Trading Day Review: Stoke Therapeutics Inc (STOK) Gains Momentum, Closing at 12.60 - The Dwinnex
FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs - MarketBeat
STOK (Stoke Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Stoke Therapeutics Inc Stock (STOK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Skorpios Trust | 10% Owner |
Dec 23 '24 |
Sale |
11.50 |
2,000,000 |
23,000,000 |
6,906,181 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):